Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clorazepate dipotassium IV for acute migraine crisis in the emergency department
2018-000503-16Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Tranxene add-on to standard treatment with Placebo add-on to standard treatment (2 arms). Primary endpoint: Pain relief at 2 hours. Started Jun 2020; status: terminated.
02
Drugs
clorazepate
03
Conditions
migraine
Beyond the preview
Go deeper on 2018-000503-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000503-16.